TG Therapeutics (TGTX) Reports Five-Year Study Showing BRIUMVI's Superior Disability Progression Outcomes in RMS

gurufocus.com · 2026-10-12

On October 12, 2026, TG Therapeutics Inc (NASDAQ: TGTX) announced results from a pivotal five-year comparative study evaluating long-term relapse rates and disa

TickrTrends take: TG Therapeutics operates in the Healthcare sector where long-term clinical evidence can substantively influence market valuation. The five-year study demonstrating BRIUMVI's superior outcomes in managing disability progression represents the type of clinical data that typically supports pricing power and market positioning for therapeutic companies. Given TickrTrends' current Undervalued assessment, investors focused on valuation metrics should monitor whether this clinical evidence translates into market share gains and revenue growth that would justify upward price movement toward fair value.

Read the full story at gurufocus.com →